ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO272

Loss of Diabetic Nephropathy Phenotype and Higher Esm-1 Map to Germline Mutation in Splicing Factor Sfswap in Inbred Mice

Session Information

Category: Diabetic Kidney Disease

  • 701 Diabetic Kidney Disease: Basic

Authors

  • Narang, Keshav, Stanford University School of Medicine, Stanford, California, United States
  • Guan, Haochen, Stanford University School of Medicine, Stanford, California, United States
  • Luo, Xiao Ran, Stanford University School of Medicine, Stanford, United States
  • Nandal, Randeep S., Stanford University School of Medicine, Stanford, California, United States
  • Maxim, Demetri, Stanford University School of Medicine, Stanford, California, United States
  • Zheng, Xiaoyi, Stanford University School of Medicine, Stanford, California, United States
  • Bhalla, Vivek, Stanford University School of Medicine, Stanford, California, United States
Background

Only a subset of diabetic DBA/2 DN-susceptible mice develop albuminuria and glomerular leukocyte infiltration. Plasma levels of endothelial cell-specific molecule-1, Esm-1, an anti-inflammatory, secreted proteoglycan inversely correlate with albuminuria in mice and humans. Moreover, over-expression of Esm-1 in diabetic DN-susceptible mice prevents albuminuria and podocyte injury independent of blood glucose. Given an inverse correlation of Esm-1 and features of DN that we observed across generations of inbred mice, we explored the genetic regulation of plasma Esm-1 and susceptibility to DN.

Methods

Genomic DNA was extracted from frozen kidney tissue of N=4 mice / generation from before and after a loss of the DN phenotype and rise in plasma Esm-1. Next-generation sequencing (NGS) of 2x150 bp PCR-free paired-end libraries was performed on a NovaSeq 6000 S4 sequencer to a coverage depth of 30x. NGS data were analyzed using the Genome Analysis Toolkit pipeline for variant calling. Restriction fragment length Polymorphism with StuI and Sanger sequencing at a candidate variant locus were used to validate NGS data in N=21 non-diabetic mice across five generations.

Results

We identified a missense variant (nt 1407 CàA, Asn469Lys (N469K) in the Splicing Factor, Arginine/Serine-Rich 8 (Srsf8, Sfswap) gene. Analysis of this variant indicated a significant association of high plasma Esm-1 with presence of the homozygous variant compared to wild-type mice (4.54±0.45 vs. 1.25 ±0.26 ng/mL, p<0.0001). We found low (< 3 ng/mL) plasma Esm-1 in 10 out of 11 wild-type but only 2 out of 10 heterozygous or homozygous mutant mice. Heterozygote variant mice had an intermediate phenotype, indicating a gene dosage effect. Asn-469 is located in a binding domain indispensable for binding of Sfswap to similar splicing factors and is evolutionarily conserved. Further experiments to edit this variant in mouse endothelial cells and to quantify secreted Esm-1 are forthcoming.

Conclusion

Our findings reveal that the Sfswap mutant genotype is highly correlated with plasma Esm-1 levels in DN-susceptible mice. In addition to elucidating genetic drift within the DBA/2 mouse colony, these results may provide novel insights into the genetic regulation of Esm-1 and opposing roles of Sfswap and Esm-1 in protection from DN.

Funding

  • NIDDK Support